'Promising' Status For Faron's Traumakine In UK Opens Possibilities For Early Access, Pricing Negotiations
The UK regulator has granted a "promising designation" to Faron Pharmaceuticals' Traumakine acute respiratory distress syndrome treatment, which means the orphan drug may be made available to patients pre-approval under the early access scheme. The drug is currently in Phase III in the EU and Japan, with 420 moderate to severe ARDS patients expected to be treated.
You may also be interested in...
Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.